Breaking News Instant updates and real-time market news.

CARA

Cara Therapeutics

$12.33

0.11 (0.90%)

, RTRX

Retrophin

$24.96

0.53 (2.17%)

04:55
11/05/17
11/05
04:55
11/05/17
04:55

American Society of Nephrology to hold a conference

ASN Kidney Week 2017 is being held in New Orleans on October 31-November 5.

CARA

Cara Therapeutics

$12.33

0.11 (0.90%)

RTRX

Retrophin

$24.96

0.53 (2.17%)

ABBV

AbbVie

$92.31

1.29 (1.42%)

ALXN

Alexion

$117.95

2.32 (2.01%)

AUPH

Aurinia Pharmaceuticals

$5.82

0.06 (1.04%)

BAYRY

Bayer

$33.74

0.285 (0.85%)

CDNA

CareDx

$5.78

-0.02 (-0.34%)

CPIX

Cumberland

$7.49

-0.28 (-3.60%)

DVA

DaVita

$59.91

0.39 (0.66%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FMS

Fresenius Medical

$48.32

0.48 (1.00%)

MNK

Mallinckrodt

$30.88

0.41 (1.35%)

MRK

Merck

$56.06

0.69 (1.25%)

MDXG

MiMedx

$12.42

0.43 (3.59%)

NXTM

NxStage Medical

$26.65

-0.19 (-0.71%)

NVS

Novartis

$83.70

0.92 (1.11%)

OMER

Omeros

$14.94

1.675 (12.63%)

OPK

Opko Health

$6.57

0.03 (0.46%)

QDEL

Quidel

$39.05

0.45 (1.17%)

RARE

Ultragenyx

$49.53

1.28 (2.65%)

SNY

Sanofi

$45.74

-0.48 (-1.04%)

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 08

    Nov

  • 08

    Nov

  • 09

    Nov

  • 09

    Nov

  • 10

    Nov

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 16

    Nov

  • 16

    Nov

  • 16

    Nov

  • 16

    Nov

  • 30

    Nov

  • 30

    Nov

  • 04

    Dec

  • 09

    Dec

  • 14

    Dec

  • 02

    Feb

  • 17

    Apr

  • 17

    May

CARA Cara Therapeutics
$12.33

0.11 (0.90%)

06/30/17
JANY
06/30/17
DOWNGRADE
Target $21
JANY
Neutral
Cara Therapeutics downgraded to Neutral from Buy at Janney Capital
Janney Capital analyst Ken Trbovich said the results of Cara Therapeutics' first placebo-controlled study of oral CR845 do not mean the end to development of the agent for chronic pain, but they also do not allow Cara to advance to a pivotal study next year, as he believes investors were expecting. Given that the pivotal study for this program has been pushed out to 2019/2020 from 2018 and that these results, combined with the decision a week ago to increase enrollment in the ongoing adaptive Phase 3 study of I.V. CR845 in postsurgical pain, gives him less confidence in a positive outcome for the Phase 3 than he'd previously had, Trbovich downgraded Cara to Neutral from Buy and lowered his fair value estimate to $21 from $22.
06/30/17
HCWC
06/30/17
NO CHANGE
Target $30
HCWC
Buy
Cara study results 'could have been far worse,' says H.C. Wainwright
H.C. Wainwright analyst Corey Davis says that even though Cara Therapeutics missed the primary endpoint in its Phase 2 study with oral CR845 in osteoarthritis pain, the company "unequivocally showed" a positive signal in the pre-specified subset of patients with hip osteoarthritis, but not knee. Most importantly, CR845 showed an "incredibly benign side effect profile," Davis tells investors in a research note. The analyst calls CR845 the first ever successful proof of concept study for an oral kappa opioid with virtually no side effects. The study "could have been far worse," and while not an obvious win that allows progression to Phase 3, the next step will be to conduct another Phase 2 with changes that can optimize the chances of CR845 showing clear efficacy. Davis keeps a Buy rating on Cara shares with a $30 price target. The stock in premarket trading is down 29%, or $7.52, to $17.99.
06/30/17
PIPR
06/30/17
NO CHANGE
Target $27
PIPR
Overweight
Cara Therapeutics selloff a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Charles Duncan believes last night's Phase II trial results from Cara Therapeutics with oral CR845 in osteoarthritis hip and knee pain are "encouraging" at the highest 5mg dose. These results suggest oral CR845 has analgesic efficacy, with a differentiated safety/tolerability profile for a chronic agent, Duncan tells investors in a research note. He recommends using any stock weakness as a buying opportunity and keeps an Overweight rating on Cara with a $27 price target.
06/30/17
06/30/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Celgene (CELG) downgraded to Neutral from Buy at BTIG with analyst Dane Leone citing a reduction in Mongersen and Ozanimod estimates. 2. Cara Therapeutics (CARA) downgraded to Neutral from Buy at Janney Capital with analyst Ken Trbovich saying the results of Cara Therapeutics' first placebo-controlled study of oral CR845 do not mean the end to development of the agent for chronic pain, but they also do not allow Cara to advance to a pivotal study next year, as he believes investors were expecting. 3. AmerisourceBergen (ABC) downgraded to Neutral from Buy at BofA/Merrill with analyst Steven Valiquette saying AmerisourceBergen is up 20% year-to-date but believes further upside will be difficult as data indicates generic pricing deflation accelerated in May. 4. RE/MAX Holdings (RMAX) downgraded to Underperform from Neutral at BofA/Merrill. 5. Vipshop (VIPS) downgraded to Hold from Buy at Deutsche Bank with analyst Alan Hellawell saying he has "competitive pressure and growth concerns" with June seeing industry-wide discounting. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
RTRX Retrophin
$24.96

0.53 (2.17%)

12/15/16
JMPS
12/15/16
NO CHANGE
JMPS
Experts support quick approval of Retrophin sparsentan, says JMP Securities
JMP Securities analyst Liisa Bayko says the firm's survey of experts who participated in the Phase 2 study of Retrophin's sparsentan in focal segmental glomerulosclerosis "showed strong support for accelerated approval" of the drug. Bayko reiterates a $28 price target and an Outperform rating on the shares of Retrophin.
04/06/17
WBLR
04/06/17
INITIATION
WBLR
Outperform
Retrophin initiated with an Outperform at William Blair
William Blair analyst Tim Lugo started Retrophin with an Outperform rating on expectations the company will transition from a "poster child for controversial pricing practices to a pipeline execution story."
11/21/16
BMOC
11/21/16
NO CHANGE
BMOC
Retrophin price target raised to $46 from $40 at BMO Capital
BMO Capital analyst Do Kim raised the price target on Retrophin after the company provided data on its Sparsentan treatment that the analyst views as positive. Kim now sees a 55% chance that the drug will be approved, up from 45% previously. The analyst continues to believe that the FDA might not accept proteinuria as an endpoint, but sees "growing evidence for proteinuria as a surrogate to kidney survival." Kim keeps an Outperform rating on the stock.
11/21/16
LEER
11/21/16
NO CHANGE
LEER
Outperform
Retrophin DUET data reintroduces accelerated approval optionality, says Leerink
Leerink analyst Joseph Schwartz says full DUET Phase 2b results for Retrophin's sparsentan in focal segmental glomerulosclerosis presented at the American Society of Nephrology Kidney Week meeting look "very strong" in terms of the ability of the drug to produce modified partial remissions and even some complete remissions during the 8-week double blind period. The analyst believes the "strong data" provides the company with as good an argument as ever to discuss the potential of accelerated approval with the FDA, although he notes that predicting FDA is "tough." He reiterates an Outperform rating on the shares.
ABBV AbbVie
$92.31

1.29 (1.42%)

10/27/17
PIPR
10/27/17
NO CHANGE
Target $115
PIPR
Overweight
AbbVie price target raised to $115 from $102 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss raised his price target for AbbVie to $115 saying he continues to see "substantial" upside in the shares following the company's Q3 results. The analyst, citing AbbVie's growing hematology/oncology business and a "rejuvenated" hepatitis c virus franchise, reiterates an Overweight rating on the shares.
10/26/17
PIPR
10/26/17
NO CHANGE
Target $102
PIPR
Overweight
AbbVie trials point to 'remarkable' efficacy of risankizumab, says Piper Jaffray
After AbbVie announced that three Phase 3 studies of risankizumab in moderate to severe plaque psoriasis all met their co-primary and secondary endpoints, Piper Jaffray analyst Richard Purkiss said the drug showed "remarkable efficacy" and demonstrates a substantial improvement in skin clearance over competing products. He views risankizumab, with this clinical data, as a compelling opportunity and keeps an Overweight rating and $102 price target on AbbVie shares.
10/30/17
LEER
10/30/17
NO CHANGE
Target $107
LEER
Outperform
AbbVie new long-term guidance could give stock 'legs to run,' says Leerink
Leerink analyst Geoffrey Porges notes that AbbVie reported Q3 financial results that were in-line with expectations. The biggest surprise from management's update was the confidence in their late stage immunology and oncology assets, forecasting that at least three of these clinical stage products will achieve 2025 revenue of $5B or greater, he contends. The analyst reiterates an Outperform rating on the stock, while lowering his price target on the shares to $107 from $107, and says he still anticipates "significant upside" emerging from late stage pipeline programs being de-risked in the next 1-3 quarters.
10/30/17
RHCO
10/30/17
NO CHANGE
Target $105
RHCO
Buy
AbbVie price target raised to $105 from $95 at SunTrust
SunTrust analyst John Boris raised his price target on Abbvie to $105 and maintained his Buy rating. Boris is modeling an $80M increase in sales of Humira as well as the Mavyret global HCV rollout and the pre-launch plans for its Elagolix, Rova-T, UPAD and RISA pipeline. The analyst also notes that Abbvie CEO is delivering on his long-term strategic plan, with best-in-class growth rates.
ALXN Alexion
$117.95

2.32 (2.01%)

10/30/17
PIPR
10/30/17
NO CHANGE
PIPR
Overweight
Piper says Europe may be real battleground for biosimilar Soliris threat
Piper Jaffray analyst Christopher Raymond noted that Amgen (AMGN) recently gained EU authorization to conduct a 40 patient, cross-over design Phase 3 trial comparing their biosimilar eculizumab to Alexion's (ALXN) Soliris. He also found evidence of Amgen's active opposition to Alexion's IP extension efforts in Europe. Raymond said many "breathed a sigh of relief" that Soliris' U.S. position on Soliris appears safe out to 2027, but he said these new signs make it appear the real battleground may be Europe. He keeps an Overweight rating on Alexion, stating that "while noise from this challenge won't go away," he thinks the company is well equipped to run its defense.
11/01/17
FBCO
11/01/17
NO CHANGE
Target $166
FBCO
Outperform
Alexion abstract doesn't have negative read to Phase 3 trial, says Credit Suisse
Credit Suisse analyst Alethia Young attributes today's weakness in Alexion shares to concerns following the release of an abstract to be presented at the American Society of Hematology annual meeting. However, Young doesn't think there is a read to be made around the every 8 week dose cohort because the company is using a higher dose of 3600mg in its Phase 3 trial, she tells investors. The analyst said Alexion remains a top pick and she keeps an Outperform rating and $166 price target on the stock, which is down 2% to $117.38 at midday.
10/26/17
LEER
10/26/17
NO CHANGE
Target $166
LEER
Outperform
Alexion shares may be up today over 5%, says Leerink
Leerink analyst Alethia Young think this quarter will be viewed as good enough and expects Alexion's shares to be up today around 5% or more. Although MG was approved earlier this week with a broader label, the analyst thinks the stock was weak as investors were cautious into this quarter. Overall, Young thinks stability on the commercial front and progress on the clinical side are enough for the stock to work. She reiterates an Outperform rating and $16 price target on the shares.
10/31/17
PIPR
10/31/17
NO CHANGE
Target $170
PIPR
Overweight
Piper says Amgen more credible biosimilar threat to Alexion in Europe
Piper Jaffray analyst Christopher Raymond believes Amgen's (AMGN) threat of a biosimilar alternative to Alexion Pharmaceuticals' (ALXN) Soliris may be more credible and near-term than he previously thought. The analyst highlights a Phase 3 study recently listed in the European Union's Clinical Trials Registry, which was authorized in August, as well as evidence of Amgen's active opposition to Alexion's intellectual property extension efforts in Europe. He reminds investors that two-thirds of Soliris' revenue is outside the U.S. Given this new evidence, "it would appear the real battleground may be Europe," Raymond tells investors in a research note. He keeps an Overweight rating on Alexion with a $170 price target. He views the company as well positioned to defend itself against Amgen.
AUPH Aurinia Pharmaceuticals
$5.82

0.06 (1.04%)

04/10/17
CANT
04/10/17
INITIATION
Target $14
CANT
Overweight
Aurinia Pharmaceuticals initiated with an Overweight at Cantor
Cantor initiated Aurinia Pharmaceuticals with an Overweight and a $14 price target.
09/13/17
ADAM
09/13/17
DOWNGRADE
Target $10
ADAM
Speculative Buy
Aurinia Pharmaceuticals downgraded to Speculative Buy from Buy at Canaccord
Canaccord analyst Neil Maruoka assumed coverage of Aurinia Pharmaceuticals and downgraded the stock to Speculative Buy from Buy, citing the high risks associated with biotech drug development. However, he believes the ongoing Phase III AURORA study has a good chance of success and sees Aurinia as undervalued based on the strength of data generated by voclosporin to date. Maruoka set a $10 price target on Aurinia shares.
10/06/17
GHSC
10/06/17
INITIATION
Target $10
GHSC
Buy
Aurinia Pharmaceuticals initiated with a Buy at Seaport Global
Seaport Global analyst Vernon Bernardino initiated Aurinia Pharmaceuticals with a Buy and $10 price target. The analyst said Aurinia is focused on advancing voclosporin, an investigational drug that could be the first treatment specifically approved in the US for active lupus nephritis. Bernardino believes shares could be range-bound near-term, following recent strength, through the initial stage of the ongoing AURORA Phase III clinical trial.
10/30/17
HCWC
10/30/17
NO CHANGE
Target $12
HCWC
Buy
Aurinia Pharmaceuticals price target raised to $12 from $10 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Aurinia Pharmaceuticals to $12 after the company at its recent analyst day announced plans to expand voclosporin development to include focal segmental glomerulosclerosis and minimal change disease. The analyst maintains a Buy rating on the shares.
BAYRY Bayer
$33.74

0.285 (0.85%)

10/17/17
NEED
10/17/17
NO CHANGE
Target $33
NEED
Buy
Exelixis price target raised to $33 from $30 at Needham
Needham analyst Chad Messer raised his price target on Exelixis (EXEL) to $33, noting the latest trial data for advanced renal cell carcinoma treatment, Cabozantinib, positions it for near and long term growth. Messer says the results may be sufficient to allay competitive concerns from the recently approved Bayer (BAYRY) Stivarga, as cabozantinib offers a potentially more attractive efficacy profile.
10/03/17
RHCO
10/03/17
NO CHANGE
RHCO
TG Therapeutics has positive read through from Bayer approval, says SunTrust
SunTrust analyst Yatin Suneja believes that the FDA's decision to grant accelerated approval to Bayer's (BAYRY) Aliqopa, a PI3K-delta inhibitor, as a treatment for Relapsed/Refractory Follicular Lymphoma, bodes well for TG Therapeutics' (TGTX) own PI3K-delta inhibitor, TGR-120. The analyst says that the lack of a black box warning on Bayer's Aliqopa shows that not all PI3K-delta inhibitors have the safety issues that have been attributed to them in the past. Suneja says that "Aliqopa's approval reflects positively on TGR-1202, which offers best-in-class safety , and provides clarity on TGR-1202's regulatory pathway in" lymphoma The analyst says that investors are "overlooking" its potential in " lymphoma, and keeps a Buy rating on the shares.
10/16/17
JEFF
10/16/17
NO CHANGE
Target $115
JEFF
Buy
Jefferies ups price target on top global pick AbbVie to $115
Jefferies analyst Jeffrey Holford keeps AbbVie (ABBV) as his top global Pharmaceuticals pick for October, followed by Roche (RHHBY), Novartis (NVS), Bayer (BAYRY), Johnson & Johnson (JNJ), Eli Lilly (LLY) and GlaxoSmithKline (GSK). The analyst raised his price target for AbbVie shares to $115 from $107 and keeps a Buy rating on the name. Among his other target changes include bumping Eli Lilly's to $100 from $96.
10/16/17
RHCO
10/16/17
NO CHANGE
Target $35
RHCO
Buy
Cabo result better positions Exelixis as acquisition target, says SunTrust
SunTrust analyst Peter Lawson raised his price target on Exelixis (EXEL) to $35 from $33 and maintained his Buy rating, saying the latest CELESTIAL trial cabozantinib positions the treatment well against its main competitor - Bayer's (BAYRY) Regorafenib. Lawson adds that the trial result validates the expansion of cabozantinib beyond kidney cancer and better positions Exelixis as a potentially attractive M&A target.
CDNA CareDx
$5.78

-0.02 (-0.34%)

08/24/17
PIPR
08/24/17
NO CHANGE
PIPR
Overweight
CareDx receives final Palmetto coverage for AlloSure, says Piper Jaffray
Piper Jaffray analyst William Quirk reported that Palmetto has issued a final local coverage determination for AlloSure that is nearly identical to the draft LCD issued in May, noting that Noridian must also finalize its LCD before CareDx can bill Medicare. Noridian "typically follows Palmetto's lead relatively quickly," added Quirk, who has an Overweight rating on CareDx.
09/26/17
PIPR
09/26/17
NO CHANGE
Target $7
PIPR
Overweight
Piper says CareDx story changed today, ups target to $7 from $3
Piper Jaffray analyst William Quirk raised his price target for CareDx to $7 from $3 after Molecular Diagnostics Services set the price for AlloSure at $2,840.75, well above his $1,500 forecast. CareDx in morning trading is up 30%, or $1.01, to 4.34. The analyst adds that Noridian, the Medicare Administrator Contractor who pays CareDx, will begin covering AlloSure on October 9. AlloSure's price is "much better than expectations and helps jump-start the company's move to profitability," Quirk tells investors in a research note. He believes the story for CareDx changed today and reiterates an Overweight rating on the shares.
09/27/17
RAJA
09/27/17
UPGRADE
Target $6.5
RAJA
Outperform
CareDx upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Nicholas Jansen upgraded CareDx to Outperform and established a $6.50 price target following positive reimbursement news by the CMS that offers a 14% increase in reimbursement to the core AlloMap test. Jansen sees significant growth in 2018 and 2019 now that the reimbursement picture is clear and AlloSure is set to launch soon and raised his 2018 revenue estimate to $62.2M, up 11%.
10/09/17
CHLM
10/09/17
NO CHANGE
Target $10
CHLM
Buy
CareDx price target raised to $10 from $4 at Craig-Hallum
Craig-Hallum analyst Kevin Ellich raised his price target for CareDX to $10 from $4, while reiterating a Buy rating on the shares as the recently completed equity offering should help bridge the gap as the company commercializes AlloSure. The analyst believes uptake of the company's non-invasive kidney transplant surveillance test will be solid leading to profitability in the next 12 months.
CPIX Cumberland
$7.49

-0.28 (-3.60%)

DVA DaVita
$59.91

0.39 (0.66%)

10/10/17
KEYB
10/10/17
NO CHANGE
KEYB
Sector Weight
DaVita estimates lowered at KeyBanc
KeyBanc analsyt Jason Gurda lowered DaVita estimates to to reflect commercial pricing/mix pressure as scrutiny over patients receiving charitable premium assistance from the AKF intensifies. The analyst said some insurers are already taking a more aggressive stance, by actively denying or voiding coverage for those patients and/or directly suing dialysis providers. Gurda lowered his 2018 EBIT estimate by $100M and 2019 by $140M and maintains a Sector Weight rating on DaVita shares.
10/09/17
JPMS
10/09/17
DOWNGRADE
Target $51
JPMS
Underweight
DaVita downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Gary Taylor downgraded DaVita to Underweight and cut his price target for the shares to $51 from $66. The American Kidney Fund's updated disclosures heighten concerns regarding the level of earnings power that DaVita derives from AKF operations, Taylor tells investors in a research note.
06/26/17
06/26/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. GrubHub (GRUB) downgraded to Equal Weight from Overweight by Morgan Stanley analyst John Glass, who lowered his price target to $43 from $47. The firm's survey results indicate 26% of Amazon (AMZN) Prime members have tried Amazon Restaurants in the past 6 months, and other players such as UberEATS and YelpEat24 are emerging, which longer-term will reduce GrubHub's profitability and cash flow, the analyst argues. 2. Stratasys (SSYS) downgraded to Sell from Neutral by Goldman Sachs analyst Matthew Cabral, who noted that the shares are up 67% year-to-date while competition is ramping and price pressure is mounting. 3. DaVita (DVA) downgraded to Hold from Buy by Jefferies analyst Chris Cooper, who cites slowing treatment growth and the "tight" rate environment. 4. Agios Pharmaceuticals (AGIO) downgraded to Neutral by Janney Capital analyst Debjit Chattopadhyay, who believes peak sales estimates for its acute myeloid leukemia treatment are likely to move lower over time. 5. American Electric (AEP) was downgraded to Neutral from Buy while Ameren (AEE) and WEC Energy (WEC) were both downgraded to Sell from Neutral at Goldman Sachs, where analyst Michael Lapides downgraded the Utilities sector to Cautious from Neutral saying valuations now appear stretched while earnings growth appears relatively normal. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/23/17
WOLF
10/23/17
UPGRADE
WOLF
Outperform
DaVita upgraded to Outperform from Peer Perform at Wolfe Research
DNA Bought by RHHBY
$0.00

(0.00%)

10/13/17
KEYB
10/13/17
NO CHANGE
Target $106
KEYB
Overweight
Auto suppliers supported by stronger Euro and rising EU output, says KeyBanc
KeyBanc analyst Brett Hoselton raised his profit targets on several auto suppliers, maintaining a positive view on the group overall heading into Q3 earnings. Hoselton says the outlook for the quarter is intact, as lower than expected production of light vehicles was in part offset by stronger EU output. He also cites FX tailwinds, with the Euro have appreciated about 7% sequentially and further supporting revenue in Q3 and possibly FY18. Hoselton raised his profit targets on Delphi Automotive (DLPH) to $106 from $100, Magna International (MGA) to $59 from $55, Lear Corp (LEA) to $184 from $180, and BorgWarner (BWA) to $56 from $50, maintaining an Overweight rating on all these stocks. The analyst is especially bullish on Dana Inc (DNA) given the recent upward revisions to North America Class 8 production, but says his Sector Weight rating reflects the stock prices.
FMS Fresenius Medical
$48.32

0.48 (1.00%)

03/21/17
UBSW
03/21/17
DOWNGRADE
UBSW
Neutral
Fresenius SE downgraded to Neutral from Buy at UBS
UBS analyst Ian Douglas-Pennant downgraded Fresenius Medical Care (FMS) two notches, to Sell from Buy, and downgraded parent Fresenius SE (FSNUY) to Neutral from Buy on read through from the downgrade of its subsidiary. He cut his price target on Fresenius SE to EUR74 from EUR75.
04/10/17
RBCM
04/10/17
NO CHANGE
RBCM
Akorn stock already reflects full take-out value, says RBC Capital
RBC Capital analyst Randall Stanicky says that the take-out valuation of drug companies have recently dropped to the historical level of 12 times EBITDA, while Akorn's take-out valuation may be "modestly lower" given the "depressed valuation" of the "generic sector." Consequently, after Bloomberg reported that Fresenius is in talks to acquire Akorn, and Akorn's stock jumped, Stanicky believes that the shares, which have reached 13 times EBITDA in pre=market trading, are fully valued. He does not see another "obvious" buyer for Akorn and keeps a Sector Perform rating on the shares.
08/22/17
GABE
08/22/17
NO CHANGE
GABE
Akorn deal still likely to close, says Gabelli
Gabelli says that Akorn's (AKRX) stock fell below $32 last week on worries that Fresenius (FMS) could restructure or break its deal to acquire the company. However, the firm still expects the deal to close, by early next year, as it does not believe that Fresenius' "disappointing" Q2 results or subpoenas related to the pricing of individual drugs would trigger the deal's material adverse event clause. Gabelli keeps a Hold rating on Akorn.
08/22/17
08/22/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Mylan (MYL) downgraded to Hold from Buy at Argus with analyst Jasper Hellweg citing the cut in 2017 guidance. He said Mylan may also have difficulty improving operations in the near-term due to unfavorable EpiPen regulatory developments, pricing pressures, and increased competition. 2. Brookfield (BIP) downgraded to Neutral from Outperform at Credit Suisse, with analyst Andrew Kuske saying he is exiting his long "tactical trade" given recent outperformance. 3. Global Medical REIT (GMRE) downgraded to Neutral from Buy at DA Davidson with analyst Barry Oxford saying that the stock "could be range bound for a period of time" following the departures of the REIT's CEO and CFO and due to "potential concerns regarding the dividend and acquisitions." 4. NxStage Medical (NXTM) downgraded to Market Perform from Outperform at Leerink, as analyst Danielle Antalffy said it is unlikely another bidder will top Fresenius Medical's (FMS) $30 per share offer for the company. 5. Hikma (HKMPY) downgraded to Neutral from Buy at Goldman Sachs, with analyst Yulia Gerasimova citing Roxane integration issues, delayed generic Advair approval, ongoing U.S. generics pricing erosion, and multiple guidance downgrades from the company. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MNK Mallinckrodt
$30.88

0.41 (1.35%)

11/03/17
HCWC
11/03/17
DOWNGRADE
Target $1.75
HCWC
Neutral
Ocera Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce downgraded Ocera Therapeutics (OCRX) to Neutral saying he does not expect competing takeover bids to rival Mallinckrodt's (MNK). The analyst has a $1.75 price target for the shares.
10/05/17
10/05/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Mallinckrodt (MNK) downgraded to Hold from Buy at Canaccord with analyst Dewey Steadman saying he sees a lack of near-term catalysts and believes the story will take time to evolve. 2. GrubHub (GRUB) downgraded to Neutral from Buy at Citi with analyst Mark May citing valuation with the shares up 44% year-to-date. 3. Coach (COH) downgraded to Neutral from Overweight at Piper Jaffray with analyst Erinn Murphy saying the stock is likely to enter a "period of digestion" as the company integrates Kate Spade and as investors "grapple with" its new reporting structure. 4. PNC Financial (PNC) downgraded to Equal Weight from Overweight at Stephens with analyst Terry McEvoy saying he views the shares as fairly valued following the stock's outperformance relative to Super Regional bank peers year-to-date. 5. Six Flags (SIX) downgraded to Long-Term Buy from Buy at Hilliard Lyons with analyst Jeffrey Thomison citing recent share appreciation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/02/17
BMOC
11/02/17
NO CHANGE
BMOC
Outperform
Mallinckrodt bolsters pipeline with 'interesting' Ocera deal, says BMO Capital
BMO Capital analyst Gary Nachman believes Mallinckrodt (MNK) is taking the right approach with a deal to buy Ocera Therapeutics (OCRX) for a "very modest" upfront plus a contingent value right. With the deal, Mallinckrodt bolsters its pipeline and reduces concentration risk for Acthar, Nachman said. The analyst, who thinks Ocera's OCR-002 could have significant potential, reiterates an Outperform rating on Mallinckrodt shares.
10/06/17
UBSW
10/06/17
NO CHANGE
Target $70
UBSW
Buy
Mallinckrodt investors should stay the course, says UBS
UBS analyst Marc Goodman admitted Mallinckrodt remains a controversial name, but he recommends investors stay the course. The analyst said his takeaway from the recent analyst day supports his positive view of the company and he believes its pipeline has several potential commercial successes. Goodman reiterated his Buy rating and $70 price target on Mallinckrodt shares.
MRK Merck
$56.06

0.69 (1.25%)

11/03/17
STFL
11/03/17
NO CHANGE
Target $25
STFL
Buy
NewLink Genetics price target lowered to $25 from $29 at Stifel
Stifel analyst Stephen Willey trimmed his price target on NewLink Genetics (NLNK) to $25 from $29 to reflect incremental dilution from its recent equity fundraising and forecast for increased operating expenses given that the company will soon initiate its pivotal Phase 3 melanoma trial. The analyst, who expects NewLink shares to remain sensitive to near-term data points on the IDO inhibitor front from Bristol-Myers (BMY) and the partnership of Incyte (INCY) and Merck (MRK), keeps a Buy rating on NewLink shares.
10/31/17
10/31/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Microsoft (MSFT) upgraded to Buy from Hold at Argus with analyst Joseph Bonner saying Microsoft is positioned to grow its commercial revenue within its "massive" commercial user base. 2. Cerner (CERN) upgraded to Outperform from Neutral at Baird with analyst Matthew Gillmor citing improved sentiment, expectations for revenue and earnings growth acceleration, and its discounted valuation. 3. Cabot Oil & Gas (COG) upgraded to Buy from Hold at Johnson Rice. 4. Merck (MRK) upgraded to Hold from Underperform at Jefferies with analyst Jeffrey Holford saying the sharp decline in the shares over the past few trading days has removed much of the downside. 5. Simpson Manufacturing (SSD) was upgraded to Outperform from Neutral at Baird and to Buy from Neutral at DA Davidson. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/31/17
JEFF
10/31/17
UPGRADE
Target $55
JEFF
Hold
Merck upgraded to Hold from Underperform at Jefferies
Jefferies analyst Jeffrey Holford upgraded Merck (MRK) to Hold and bumped up his price target for the shares to $55 from $54. The healthcare company closed yesterday down 6% to $54.71. The sharp decline in the shares over the past few trading days has removed much of the downside, Holford tells investors in a research note partially titled "Keytruda Bulls Neutralized." Merck remains the analyst's least preferred stock. He believes Roche (RHHBY) may benefit most from the Keytruda delays.
10/30/17
10/30/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. General Motors (GM) downgraded to Sell from Neutral at Goldman Sachs with analyst David Tamberrino saying his price target of $32 offers 28% potential downside. The analyst continues to believe the North America auto cycle has peaked and he remains cautious on the sector. 2. Merck (MRK) downgraded to Hold from Buy at SunTrust and to Equal Weight from Overweight at Morgan Stanley, as well as Barclays. 3. J.C. Penney (JCP) downgraded to Sell from Neutral at Citi, to Neutral from Buy at Northcoast, and to Neutral from Positive at Susquehanna. 4. Macy's (M) downgraded to Sell from Neutral at Citi with analyst Paul Lejuez saying the retailer's sales and margins have been pressured for several years, and J.C. Penney's weak third quarter preannouncement on Friday serves as reminder of just how challenging the department store space is. 5. Under Armour (UAA, UA) downgraded to Underperform from Neutral at BofA/Merrill with analyst Robert Ohmes saying he expects management to lower fourth quarter guidance on its Q3 conference call due to the highly promotional environment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MDXG MiMedx
$12.42

0.43 (3.59%)

10/30/17
PIPR
10/30/17
NO CHANGE
Target $18
PIPR
Overweight
Piper Jaffray continues to recommend purchase of MiMedx
Piper Jaffray analyst Matt O'Brien sees room for multiple expansion and upside to revenue estimates at MiMedx Group. The analyst views the company's Q3 results as strong and thinks its "excellent product" will continue to drive sales results. O'Brien continues to recommend purchase of the shares with an Overweight rating and $18 price target.
09/06/17
NEED
09/06/17
NO CHANGE
NEED
MiMedx should get revenue boost from VLU indication, says Needham
After MiMedx announced that its venous leg ulcer, or VLU, randomized controlled trial was accepted for publication in The International Wound Journal, Needham analyst Mike Matson thinks the results are favorable versus a competing treatment, Organogenesis Apligraf. He estimates that coverage of the VLU indication could generate $75M-$150M of incremental revenue for MiMedx in 2018. He raised his price target on the shares to $21 from $20 and keeps a Strong Buy rating on the stock.
09/05/17
PIPR
09/05/17
NO CHANGE
PIPR
Overweight
MiMedx yearly guidance likely to be raised with Q3 release, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien noted the strong momentum MiMedx saw in the first half has continued into Q3. While the company said it sees beating its Q3 revenue guidance but left its full year view unchanged for now, he "fully" expects guidance will be raised with its Q3 report. O'Brien recommends investors become increasingly aggressive on pullbacks in MiMedx and keeps an Overweight rating on the shares.
09/22/17
PIPR
09/22/17
NO CHANGE
Target $18
PIPR
Overweight
MiMedx shares offer 'highly attractive entry point,' says Piper Jaffray
Piper Jaffray analyst Matt O'Brien believes the recent pullback in shares in MiMedx Group brings a "highly attractive entry point." Short reports can have a dramatic impact in the short term, but generally end up immaterial, O'Brien tells investors in a research note after MiMedx hosted a business update call and addressed the recent reports. He believes the company has multiple catalysts to drive "significant" revenue growth in the coming years and drive the multiple higher as it transitions to a biopharma company. O'Brien has an Overweight rating on MiMedx with an $18 price target.
NXTM NxStage Medical
$26.65

-0.19 (-0.71%)

08/22/17
LEER
08/22/17
DOWNGRADE
LEER
Market Perform
NxStage Medical downgraded to Market Perform from Outperform at Leerink
Leerink analyst Danielle Antalffy downgraded NxStage Medical (NXTM) to Market Perform saying it is unlikely another bidder will top Fresenius Medical's (FMS) $30 per share offer for the company.
08/09/17
SPHN
08/09/17
DOWNGRADE
SPHN
Equal Weight
NxStage Medical downgraded to Equal Weight from Overweight at Stephens
NxStage Medical (NXTM) has agreed to be acquired by Fresenius Medical Care (FMS) for $30 per share.
08/08/17
JEFF
08/08/17
DOWNGRADE
Target $30
JEFF
Hold
NxStage Medical downgraded to Hold from Buy at Jefferies
Jefferies analyst Raj Denhoy downgraded NxStage Medical to Hold citing limited competing bidders and a potentially lengthy close due to antitrust questions. The analyst views Fresenius as the "most logical and likely only buyer" of the company. He lowered his price target for the shares to $30 from $33 following yesterday's deal announcement.
NVS Novartis
$83.70

0.92 (1.11%)

10/31/17
LEER
10/31/17
NO CHANGE
Target $37
LEER
Outperform
Intellia Therapeutics price target raised to $37 from $29 at Leerink
Leerink analyst Joseph Schwartz said Intellia Therapeutics' (NTLA) demonstration of gene editing across multiple animal models brings the company one-step closer to an IND filing. He also believes investors are pricing in an M&A premium following Gilead's (GILD) acquisition of Kite and the approvals of Novartis' (NVS) Kymriah and Gilead's Yescarta. Noting that his valuation "now incorporates a very small fraction" of the Kite acquisition value, he raised his price target on Intellia to $37 from $29 and keeps an Outperform rating on the shares.
10/30/17
JMPS
10/30/17
DOWNGRADE
JMPS
Market Perform
Advanced Accelerator downgraded to Market Perform at JMP Securities
JMP Securities analyst Michael King downgraded Advanced Accelerator (AAAP) to Market Perform from Outperform saying a competing takeover bid to Novartis' (NVS) is unlikely.
10/25/17
LEHM
10/25/17
DOWNGRADE
LEHM
Underweight
Novartis downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Emmanuel Papadakis downgraded Novartis to Underweight and cut his price target for the shares to CHF 75 from CHF 80. Following the Q3 results, the analyst believes Entresto estimates remain too high and that competitive pressure increasing for Cosentyx. He sees a lack of catalysts in the near-term beyond RTH258.
10/20/17
10/20/17
DOWNGRADE
Target $0.9

Hold
Durect downgraded to Hold on 'major disappointment' of Posimir failure at Stifel
As previously reported, Stifel analyst Adam Walsh downgraded Durect (DRRX) to Hold from Buy, calling the fact that the company's Phase 3 Posimir trial in post-surgical pain did not meet its primary efficacy endpoint a "major disappointment." He has removed all Posimir revenue from his model and expects Novartis' (NVS) Sandoz will end the Posimir partnership. Walsh lowered his price target to 90c from $3.00 on Durect shares, which are down 55% to 87c in pre-market trading.
OMER Omeros
$14.94

1.675 (12.63%)

11/02/17
COWN
11/02/17
DOWNGRADE
COWN
Market Perform
Omeros downgraded to Market Perform from Outperform at Cowen
05/11/17
CANT
05/11/17
DOWNGRADE
Target $15
CANT
Neutral
Omeros downgraded to Neutral from Overweight at Cantor
Cantor analyst Elemer Piros downgraded Omeros to Neutral and lowered its price target to $15 from $21 following the slightly weaker than expected Q1 report. The analyst has tempered his estimates for the US commercial ramp in peak market penetration to 25% from 30% and views shares as fully valued.
OPK Opko Health
$6.57

0.03 (0.46%)

09/14/17
JPMS
09/14/17
DOWNGRADE
Target $7
JPMS
Neutral
OPKO Health downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Eric Joseph downgraded OPKO Health to Neutral and cut his price target for the shares to $7 from $12. The healthcare company closed yesterday down 22c to $6.25. Key recent product launches have struggled while contributions from the pharma pipeline over the near- and mid-term are only going to be "incremental," Joseph tells investors in a research note.
08/18/17
08/18/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Pointer Telocation (PNTR) initiated with a Buy at B. Riley. 2. Heron Therapeutics (HRTX) assumed with an Overweight at Cantor. 3. OPKO Health (OPK) initiated with an Overweight at Cantor. 4. Floor & Decor (FND) initiated with a Hold at Loop Capital. 5 TPG RE Finance (TRTX) initiated with an Outperform at JMP Securities and a Buy at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/18/17
CANT
08/18/17
INITIATION
Target $20
CANT
Overweight
OPKO Health initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started OPKO Health with an Overweight rating and $20 price target. The uptake of Rayaldee, commercialization of the company's branded drug pipeline, and BioReference sales growth should drive upward earnings revisions, Chen tells investors in a research note. The healthcare company closed yesterday down 18c to $5.88.
08/03/17
BRRR
08/03/17
DOWNGRADE
BRRR
Underperform
PharMerica downgraded to Underperform from Outperform at Barrington
Barrington analyst Michael Petusky double downgraded PharMerica (PMC) to Underperform saying other takeover bidders are unlikely to emerge. The analyst suggests redeploying proceeds into Tivity Health (TVTY), Primo Water (PRMW), U.S. Physical Therapy (USPH) and OPKO Health (OPK).
QDEL Quidel
$39.05

0.45 (1.17%)

07/18/17
WBLR
07/18/17
UPGRADE
WBLR
Outperform
Quidel upgraded to Outperform from Market Perform at William Blair
William Blair analyst Brian Weinstein upgraded Quidel to Outperform following the company's acquisition of Alere's Triage assets. Canaccord Genuity this morning also upgraded the shares.
07/18/17
ADAM
07/18/17
UPGRADE
Target $42
ADAM
Buy
Quidel upgraded to Buy from Hold at Canaccord
Canaccord analyst Mark Massaro upgraded Quidel (QDEL) to Buy from Hold as it is a beneficial buyer of Alere (ALR) assets. The analyst said the deal doubles the company's revenues, is immediately accretive, was bought at a low multiple to market value, and provides the company with new platforms to add tests on. Massaro raised his price target to $42 from $25 on Quidel shares.
09/19/17
PIPR
09/19/17
UPGRADE
Target $50
PIPR
Overweight
Quidel upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst William Quirk upgraded Quidel (QDEL) to Overweight and raised his price target for the shares to $50 from $35. The stock can continue to rise as investors digest how accretive the updated Alere (ALR) deal is and become more comfortable with an Abbott (ABT)/Alere deal close, Quirk tells investors in a research note. To reflect the amended deal agreement, the analyst raised his 2018 earnings estimates for Quidel by 64%.
09/19/17
LEHM
09/19/17
NO CHANGE
Target $45
LEHM
Overweight
Quidel price target raised to $45 from $39 at Barclays
Barclays analyst Jack Meehan raised his price target for Quidel shares to $45 citing improved accretion and visibility following the company's amended agreement to acquire the Triage and BNP businesses. The analyst continues to support the acquisition and keeps an Overweight rating on Quidel. Piper Jaffray this morning upgraded the shares.
RARE Ultragenyx
$49.53

1.28 (2.65%)

10/03/17
WELS
10/03/17
DOWNGRADE
WELS
Market Perform
Dimension Therapeutics downgraded to Market Perform at Wells Fargo
Ultragenyx Pharmaceutical (RARE) has agreed to acquire Dimension Therapeutics (DMTX) for $6.00 per share, or approximately $151M in cash.
10/03/17
SBSH
10/03/17
UPGRADE
Target $6
SBSH
Neutral
Dimension Therapeutics upgraded to Neutral from Sell at Citi (yesterday)
Citi analyst Joel Beatty yesterday upgraded Dimension Therapeutics (DMTX) to Neutral saying the company is likely to be acquired at Ultragenyx's (RARE) $6 per share all case offer. The analyst finds it unlikely that another company will come in with a new and higher offer.
09/19/17
WEDB
09/19/17
NO CHANGE
Target $62
WEDB
Outperform
Ultragenyx bid for Dimension adds promising gene therapy pipeline, says Wedbush
Wedbush analyst David Nierengarten says that a successful acquisition of Dimension Therapeutics (DMTX) would mark Ultragenyx's (RARE) entry into the gene therapy space, and would be a natural extension of the latter's rare disease focus. The analyst expects the bid to go through. Nierengarten reiterates an Outperform rating and $62 price target on Ultragenyx shares.
09/19/17
BARD
09/19/17
NO CHANGE
BARD
Outperform
Ultragenyx deal for Dimension would be good strategic fit, says Baird
Baird analyst Michael Ulz noted Ultragenyx (RARE) topped Regenxbio's (RGNX) bid for Dimension Therapeutics (DMTX) with a $5.50 per share offer of its own. He views the proposed acquisition of Dimension as a good strategic fit that would add a gene therapy platform and expand the early-stage pipeline. Ulz keeps an Outperform rating on Ultragenyx shares.
SNY Sanofi
$45.74

-0.48 (-1.04%)

10/31/17
ADAM
10/31/17
NO CHANGE
Target $35
ADAM
Buy
Voyager Therapeutics buy thesis based on standalone value, says Canaccord
Canaccord analyst Sumant Kulkarni noted Sanofi (SNY) decided not to exercise its ex-U.S. rights to Voyager Therapeutics' (VYGR) gene therapy candidate for advanced Parkinson's disease. The analyst believes the U.S. market is more valuable and he based his Buy thesis on the company's standalone value. He still likes Voyager shares despite Sanofi's decision and views any pullback as a buying opportunity. Kulkarni reiterated his Buy rating and $35 price target on Voyager Therapeutics shares.
10/31/17
WEDB
10/31/17
NO CHANGE
Target $31
WEDB
Outperform
Voyager Therapeutics price target lowered to $31 from $36 at Wedbush
Wedbush analyst David Nierengarten lowered his price target for Voyager (VYGR) to $31 from $36 following Sanofi's (SNY) decision to not opt-in ex-U.S. rights to VY-AADC, despite positive Phase 1 experience, which he views as an assessment of commercial opportunity for gene therapies outside U.S., rather than a reflection of VY-AADC's clinical profile. The analyst expects Voyager to carry VY-AADC to registration in ex-U.S. regions without a partner, although resources will likely be focused on opportunity in U.S. where a stronger reimbursement environment exists. Nierengarten continues to see Voyager shares as undervalued, and reiterates an Outperform rating on the stock.
11/02/17
PIPR
11/02/17
NO CHANGE
Target $540
PIPR
Overweight
Sanofi's Dupixent sales in Q3 'crushed it,' says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says Sanofi's (SNY) revenue numbers this morning for Dupixent came in well ahead of anyone's expectations. Worldwide Dupixent sales of $87M "crushed it" versus the consensus of $70M and Piper's estimate of $82M, Raymond tells investors in a research note on Regeneron Pharmaceuticals (REGN). The launch continues to show strength, the analyst contends. He has an Overweight rating on Regeneron with a $540 price target.
10/31/17
NOMU
10/31/17
NO CHANGE
Target $31
NOMU
Buy
Sanofi opting out more valuable option for Voyager, says Nomura
Nomura Instinet analyst Christopher Marai says Sanofi-Genzyme (SNY) not opting into the outside U.S. development of Voyager Therapeutics's (VYGR) VY-AADC PD program is the more valuable of two possible outcomes for shareholders. Voyager consequently gains the worldwide rights to its compound, Marai tells investors in a research note. He points out that he did not model an ex-US collaboration and that the remaining Sanofi collaboration remains in place. Voyager's pipeline offers "potentially significant upside" to the shares with the translation of pre-clinical to clinical data points, Marai contends. He keeps a Buy rating on the shares with a $31 price target. The stock last night traded down 10% to $20.50.

TODAY'S FREE FLY STORIES

KORS

Michael Kors

$68.63

0.25 (0.37%)

, LULU

Lululemon

$106.18

-0.19 (-0.18%)

11:07
05/26/18
05/26
11:07
05/26/18
11:07
Periodicals
Dollar Tree looks interesting, Barron's says »

Next week, another 20…

KORS

Michael Kors

$68.63

0.25 (0.37%)

LULU

Lululemon

$106.18

-0.19 (-0.18%)

GME

GameStop

$12.64

-0.1 (-0.78%)

DLTR

Dollar Tree

$95.23

0.59 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 31

    May

  • 31

    May

  • 12

    Jun

  • 14

    Jun

  • 26

    Jun

KHC

Kraft Heinz

$57.78

0.72 (1.26%)

, QCOM

Qualcomm

$59.95

0.85 (1.44%)

10:58
05/26/18
05/26
10:58
05/26/18
10:58
Periodicals
Kraft Heinz, J&J among safe, 'solid' dividend stocks, Barron's says »

Kraft Heinz (KHC),…

KHC

Kraft Heinz

$57.78

0.72 (1.26%)

QCOM

Qualcomm

$59.95

0.85 (1.44%)

MRK

Merck

$59.08

-0.03 (-0.05%)

TGT

Target

$71.22

0.28 (0.39%)

OMC

Omnicom

$71.98

-0.1 (-0.14%)

CCL

Carnival

$64.27

0.12 (0.19%)

JNJ

Johnson & Johnson

$121.40

0.06 (0.05%)

MMM

3M

$198.98

-0.38 (-0.19%)

LLY

Eli Lilly

$82.75

0.05 (0.06%)

VLO

Valero

$118.81

-3.06 (-2.51%)

EMR

Emerson

$72.50

-0.77 (-1.05%)

WBA

Walgreens Boots Alliance

$63.52

0.09 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 30

    May

  • 30

    May

  • 02

    Jun

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 07

    Jun

  • 12

    Jun

  • 19

    Jun

  • 10

    Sep

  • 23

    Oct

MU

Micron

$61.33

-0.15 (-0.24%)

10:48
05/26/18
05/26
10:48
05/26/18
10:48
Periodicals
Micron can solve low valuation, Barron's says »

Micron's stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 20

    Jun

ATUS

Altice USA

$18.50

-0.05 (-0.27%)

10:40
05/26/18
05/26
10:40
05/26/18
10:40
Periodicals
Altice's spinoff could be winning bet, Barron's says »

On June 8, Altice will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 30

    May

MU

Micron

$61.33

-0.15 (-0.24%)

, XLNX

Xilinx

$69.63

0.88 (1.28%)

10:35
05/26/18
05/26
10:35
05/26/18
10:35
Periodicals
AI revolution just getting started, Barron's says »

Artificial Intelligence…

MU

Micron

$61.33

-0.15 (-0.24%)

XLNX

Xilinx

$69.63

0.88 (1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 20

    Jun

ZTCOY

ZTE Corp.

$0.00

(0.00%)

, DDAIF

Daimler AG

$0.00

(0.00%)

08:08
05/26/18
05/26
08:08
05/26/18
08:08
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

ZTCOY

ZTE Corp.

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$21.82

-0.445 (-2.00%)

HMC

Honda

$32.04

-0.34 (-1.05%)

NSANY

Nissan

$0.00

(0.00%)

F

Ford

$11.51

-0.11 (-0.95%)

GM

General Motors

$38.30

-0.09 (-0.23%)

TM

Toyota

$129.97

-2.47 (-1.87%)

VLKAY

Volkswagen

$0.00

(0.00%)

BAC

Bank of America

$30.16

-0.03 (-0.10%)

C

Citi

$68.42

-0.86 (-1.24%)

GS

Goldman Sachs

$235.05

-1.1 (-0.47%)

JPM

JPMorgan

$110.62

-0.64 (-0.58%)

MS

Morgan Stanley

$53.02

-0.96 (-1.78%)

USB

U.S. Bancorp

$50.54

-0.14 (-0.28%)

WFC

Wells Fargo

$54.91

0.25 (0.46%)

TWTR

Twitter

$33.64

0.11 (0.33%)

AA

Alcoa

$47.92

-1.26 (-2.56%)

CENX

Century Aluminum

$16.27

-0.07 (-0.43%)

AOBC

American Outdoor Brands

$12.53

0.05 (0.40%)

RGR

Sturm, Ruger

$63.10

0.5 (0.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 30

    May

  • 01

    Jun

  • 06

    Jun

  • 20

    Jun

  • 22

    Jun

  • 13

    Jul

  • 27

    Jul

  • 10

    Sep

  • 12

    Oct

  • 14

    Jan

  • 15

    Apr

  • 15

    Jul

  • 15

    Oct

HCLP

Hi-Crush Partners

$13.20

-0.825 (-5.88%)

17:54
05/25/18
05/25
17:54
05/25/18
17:54
Hot Stocks
Hi-Crush Partners provides update on bulldozer incident in Whitehall facility »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POST

Post Holdings

$77.98

1.49 (1.95%)

17:37
05/25/18
05/25
17:37
05/25/18
17:37
Hot Stocks
Post Holdings reports fire in Michael Foods' plant in Pennsylvania »

Post Holdings reported a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

ABMD

Abiomed

$394.49

0.04 (0.01%)

, WYN

Wyndham

$107.98

-0.58 (-0.53%)

17:34
05/25/18
05/25
17:34
05/25/18
17:34
Hot Stocks
Abiomed to enter S&P 500 index on May 31 »

S&P MidCap 400…

ABMD

Abiomed

$394.49

0.04 (0.01%)

WYN

Wyndham

$107.98

-0.58 (-0.53%)

MSCC

Microsemi

$68.74

0.005 (0.01%)

PRAH

PRA Health

$81.19

0.33 (0.41%)

GME

GameStop

$12.64

-0.1 (-0.78%)

FRED

Fred's

$1.69

0.05 (3.05%)

PRSP

Symbol now PB

$0.00

(0.00%)

RRTS

Roadrunner

$2.19

0.04 (1.86%)

DXC

DXC Technology

$94.20

-5.42 (-5.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 05

    Jun

  • 12

    Jun

PRAH

PRA Health

$81.19

0.33 (0.41%)

, ABMD

Abiomed

$394.49

0.04 (0.01%)

17:24
05/25/18
05/25
17:24
05/25/18
17:24
Hot Stocks
Breaking Hot Stocks news story on PRA Health, Abiomed »

PRA Health to replace…

PRAH

PRA Health

$81.19

0.33 (0.41%)

ABMD

Abiomed

$394.49

0.04 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 05

    Jun

  • 12

    Jun

WYN

Wyndham

$107.98

-0.58 (-0.53%)

, MSCC

Microsemi

$68.74

0.005 (0.01%)

17:23
05/25/18
05/25
17:23
05/25/18
17:23
Hot Stocks
Breaking Hot Stocks news story on Wyndham, Microsemi »

Wyndham to replace…

WYN

Wyndham

$107.98

-0.58 (-0.53%)

MSCC

Microsemi

$68.74

0.005 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMD

Abiomed

$394.49

0.04 (0.01%)

, WYN

Wyndham

$107.98

-0.58 (-0.53%)

17:21
05/25/18
05/25
17:21
05/25/18
17:21
Hot Stocks
Breaking Hot Stocks news story on Abiomed, Wyndham »

ABIOMED to replace…

ABMD

Abiomed

$394.49

0.04 (0.01%)

WYN

Wyndham

$107.98

-0.58 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 05

    Jun

  • 12

    Jun

PCG

PG&E

$44.67

0.84 (1.92%)

17:16
05/25/18
05/25
17:16
05/25/18
17:16
Periodicals
CA Forestry Dept rules PG&E equipment responsible for wildfires, Bloomberg says »

Report filed by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FARM

Farmer Bros.

$28.50

0.15 (0.53%)

17:09
05/25/18
05/25
17:09
05/25/18
17:09
Hot Stocks
Levin Capital Strategies reports 8.4% stake in Farmer Bros »

Levin Capital purchased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$8.90

-0.35 (-3.78%)

17:07
05/25/18
05/25
17:07
05/25/18
17:07
Syndicate
Breaking Syndicate news story on Noodles & Company »

Noodles & Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$1.22

-0.125 (-9.29%)

17:06
05/25/18
05/25
17:06
05/25/18
17:06
Hot Stocks
Windstream completes one-for-five reverse stock split »

Windstream completed its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$8.90

-0.35 (-3.78%)

17:06
05/25/18
05/25
17:06
05/25/18
17:06
Syndicate
Breaking Syndicate news story on Noodles & Company »

Noodles & Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPD

Enterprise Products

$27.87

-0.12 (-0.43%)

17:01
05/25/18
05/25
17:01
05/25/18
17:01
Hot Stocks
Enterprise Products conduts open season for West Texas Crude oil expansion »

Enterprise Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INO

Inovio

$4.89

0.06 (1.24%)

16:37
05/25/18
05/25
16:37
05/25/18
16:37
Syndicate
Breaking Syndicate news story on Inovio »

Inovio files $250M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$10.14

0.13 (1.30%)

16:36
05/25/18
05/25
16:36
05/25/18
16:36
Hot Stocks
Rent-A-Center 16.8% shareholder Engaged Capital nominates Carol McFate to Board »

On May 25, 2018, Engaged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$0.59

0.0086 (1.48%)

16:34
05/25/18
05/25
16:34
05/25/18
16:34
Hot Stocks
Akers Biosciences receives delinquency notice from NASDAQ »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHCP

Ditech

$6.60

0.37 (5.94%)

16:31
05/25/18
05/25
16:31
05/25/18
16:31
Hot Stocks
Ditech discloses receipt of late filing notice from NYSE »

Ditech Holding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$28.15

-4.82 (-14.62%)

, FL

Foot Locker

$55.97

9.585 (20.67%)

16:30
05/25/18
05/25
16:30
05/25/18
16:30
General news
On The Fly: Top stock stories for Friday »

Stocks on Wall Street…

GPS

Gap

$28.15

-4.82 (-14.62%)

FL

Foot Locker

$55.97

9.585 (20.67%)

HLF

Herbalife Nutrition

$48.76

-5.09 (-9.45%)

IEP

Icahn Enterprises

$69.41

0.22 (0.32%)

FCAU

Fiat Chrysler

$21.82

-0.445 (-2.00%)

DGX

Quest Diagnostics

$105.89

5 (4.96%)

UNH

UnitedHealth

$244.96

2.23 (0.92%)

ROST

Ross Stores

$77.35

-5.6 (-6.75%)

ADSK

Autodesk

$132.80

-5.96 (-4.30%)

AAL

American Airlines

$44.89

1.34 (3.08%)

LUV

Southwest

$52.86

1.65 (3.22%)

DAL

Delta Air Lines

$55.89

1.48 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 30

    May

  • 30

    May

  • 12

    Jun

  • 13

    Jun

  • 14

    Jun

  • 26

    Jun

  • 29

    Jun

16:30
05/25/18
05/25
16:30
05/25/18
16:30
Options
Preliminary option volume of 16.4M today »

Preliminary option volume…

VTL

Vital Therapies

$5.65

-0.475 (-7.76%)

16:26
05/25/18
05/25
16:26
05/25/18
16:26
Syndicate
Breaking Syndicate news story on Vital Therapies »

Vital Therapies files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.